These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25981639)

  • 1. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters.
    Shimamoto K; Sakai R; Takaoka K; Yumoto N; Nakajima T; Amara SG; Shigeri Y
    Mol Pharmacol; 2004 Apr; 65(4):1008-15. PubMed ID: 15044631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.
    Esslinger CS; Agarwal S; Gerdes J; Wilson PA; Davis ES; Awes AN; O'Brien E; Mavencamp T; Koch HP; Poulsen DJ; Rhoderick JF; Chamberlin AR; Kavanaugh MP; Bridges RJ
    Neuropharmacology; 2005 Nov; 49(6):850-61. PubMed ID: 16183084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.
    Shimamoto K; Lebrun B; Yasuda-Kamatani Y; Sakaitani M; Shigeri Y; Yumoto N; Nakajima T
    Mol Pharmacol; 1998 Feb; 53(2):195-201. PubMed ID: 9463476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) during physiological and ischemia-like conditions.
    Bonde C; Sarup A; Schousboe A; Gegelashvili G; Zimmer J; Noraberg J
    Neurochem Int; 2003; 43(4-5):371-80. PubMed ID: 12742081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (PDC) and the non-substrate inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo.
    Montiel T; Camacho A; Estrada-Sánchez AM; Massieu L
    Neuroscience; 2005; 133(3):667-78. PubMed ID: 15890455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
    Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
    BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters.
    Shimamoto K; Otsubo Y; Shigeri Y; Yasuda-Kamatani Y; Satoh M; Kaneko S; Nakagawa T
    Mol Pharmacol; 2007 Jan; 71(1):294-302. PubMed ID: 17047096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate.
    Phillis JW; Ren J; O'Regan MH
    Brain Res; 2000 Jun; 868(1):105-12. PubMed ID: 10841893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate transporter dysfunction associated with nerve injury-induced pain in mice.
    Napier IA; Mohammadi SA; Christie MJ
    J Neurophysiol; 2012 Jan; 107(2):649-57. PubMed ID: 22072505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity.
    Lewerenz J; Klein M; Methner A
    J Neurochem; 2006 Aug; 98(3):916-25. PubMed ID: 16771835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C6 glioma cells differentiated by retinoic acid overexpress the glutamate transporter excitatory amino acid carrier 1 (EAAC1).
    Bianchi MG; Gazzola GC; Tognazzi L; Bussolati O
    Neuroscience; 2008 Feb; 151(4):1042-52. PubMed ID: 18207650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel glutamate transporter blocker, LL-TBOA, attenuates ischaemic injury in the isolated, perfused rat heart despite low transporter levels.
    Martinov V; Dehnes Y; Holmseth S; Shimamoto K; Danbolt NC; Valen G
    Eur J Cardiothorac Surg; 2014 Apr; 45(4):710-6. PubMed ID: 24099732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid induces the glutamate transporter excitatory amino acid transporter-3 in human oligodendroglioma cells.
    Bianchi MG; Franchi-Gazzola R; Reia L; Allegri M; Uggeri J; Chiu M; Sala R; Bussolati O
    Neuroscience; 2012 Dec; 227():260-70. PubMed ID: 23041758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
    Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.